Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Colon cancer
- Focus Therapeutic Use
- Acronyms NICHE
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 08 Sep 2017 According to the Trial design presented at the 42nd European Society for Medical Oncology Congress, recruitment for this study is ongoing and currently two patients have been enrolled.
- 23 Jan 2017 Status changed from not yet recruiting to recruiting.